Here we determined the radio-sensitizing potential of a pan-EGFR inhibitor afatinib [20, 21] and explored the mechanism by which afatinib augmented radio-sensitivity in HNSCC cancer models in vitro and in vivo. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.